Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its target price cut by Wells Fargo & Company from $28.00 to $26.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective indicates a potential upside of 134.23% from the company's previous close.
A number of other research analysts also recently weighed in on KROS. Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a report on Thursday, January 16th. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating on the stock. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. BTIG Research downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Finally, HC Wainwright lowered their price target on Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $42.33.
View Our Latest Stock Analysis on KROS
Keros Therapeutics Stock Performance
Shares of KROS stock traded up $0.02 during trading on Thursday, hitting $11.10. 1,059,503 shares of the company were exchanged, compared to its average volume of 1,610,033. The firm has a market capitalization of $449.63 million, a price-to-earnings ratio of -2.13 and a beta of 1.39. The business's 50-day simple moving average is $12.52 and its 200 day simple moving average is $39.49. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $72.37.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. On average, equities analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Keros Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock valued at $42,146,000 after purchasing an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company's stock valued at $15,105,000 after buying an additional 32,492 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $388,000. Barclays PLC grew its position in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after buying an additional 35,022 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Keros Therapeutics during the third quarter worth about $603,000. Institutional investors and hedge funds own 71.56% of the company's stock.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
